Targeted lipidomics meets transcriptomics: how cinobufagin rewires fatty acid, sphingolipid, and glycerophospholipid metabolism to combat hepatoma cell growth

Our findings demonstrate that cinobufagin exerts anti-HCC activity partially through lipid metabolism, particularly by targeting fatty acid, sphingolipid, and glycerophospholipid pathways. This study is of great significance for the application of cinobufagin and chansu in clinical HCC treatment and promotes the development of new drugs from traditional Chinese medicine in the field of antitumor.